Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)

NCT01829035 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT01829035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01829035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)
Lead sponsor
National Cancer Center, Korea
Phase
Phase 3
Overall status
Completed
Start date
February 21, 2013
Completion date
June 21, 2017
Enrollment
339 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma